Chief among its criticisms is Novavax's failure to build sales of its protein-based COVID-19 vaccine Nuvaxovid/Covovax, a ...

LC: Manufacturability is the field's most critical near-term challenge, especially for ex vivo cell therapies. Encouragingly, ...

France-based investment group Jeito Capital has closed its second fund, raking in €1 billion ($1.2 billion), which it claims ...

In modern drug discovery, successfully navigating the progress from molecular concept to viable therapeutic often hinges on ...

The EU has pledged €30 million ($35 million) in funding for medical countermeasures to antimicrobial resistance (AMR), ...

A legal bid to introduce a temporary block on remote access to the abortion pill mifepristone in the US, while the Trump ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Lance Baldo, CEO of Beacon Therapeutics, a ...

Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...

HHS Secretary Robert F Kennedy Jr has followed a court ruling that his controversial appointments to the CDC's Advisory Committee on Immunization Practices (ACIP) were unlawful by changing the panel's ...

Gilead Sciences has signed its third acquisition deal since the start of the year, agreeing to buy Germany's Tubulis and its pipeline of antibody-drug conjugates (ADCs) for cancer. Assuming the ...

The prize for Neurocrine is Soleno's Vykat XR (diazoxide choline) medicine for Prader-Willi syndrome (PWS), which was ...

Anthropic has continued its push into the healthcare sector by acquiring New York startup Coefficient Bio, a specialist in applying AI to drug discovery that was set up last year but until now has ...